Company* (Country; Symbol)




Status (Date)


Amgen Inc. (AMGN)

Enbrel (FDA-approved)

Etanercept; anti-TNF-alpha antibody

Ankylosing spondylitis

Partner Wyeth gained approval in Europe to sell the drug for those with severe, active disease (1/20)

Antisense Therapeutics Ltd. (Australia; ASX:ANP)


Second-generation antisense drug

Multiple sclerosis

Preliminary Phase I data were positive in terms of safety and pharmacokinetics (1/30)


Bioenvision Inc. (AMEX:BIV)


Next-generation purine nucleoside antimetabolite

Acute myelogenous leukemia

Phase II trial in the UK began involving older adults not suitable for intensive chemotherapy (1/14)

Biogen Idec Inc. (BIIB)

Zevalin (FDA-approved)

Ibritumomab tiuxetan; monoclonal antibody targeting CD20 combined with radioisotope

Non-Hodgkin's lymphoma

The product was approved in Europe for treating adults with CD20+ follicular B-cell NHL who are refractory to Rituxan; it will be sold there by Schering AG (1/22)

MediGene AG (Germany; FSE:MDG)

Eligard 22.5 mg

Leuprolide acetate for injectable suspension

Prostate cancer

German authorities approved the product, which was developed by Atrix Laboratories Inc. (1/26)

Millennium Pharmaceuticals Inc. (MLNM)

Velcade (FDA-approved)

Bortezomib; proteasome inhibitor

Multiple myeloma

European regulators recommended approval under exceptional circumstances for treating patients whose disease has progressed under prior treatments (1/22)

Munich Biotech AG* (Germany)


Anti-neovascular agent containing paclitaxel and a lipid-based carrier

Metastatic breast and pancreatic cancer

Company started Phase II trial in each indication; the pancreatic trial is for first-line treatment in combination with gemcitabine in 70 patients; the breast cancer trial is a second- or third-line monotherapy trial in 60 patients (1/16)

Oxford BioMedica plc (UK; LSE:OXB)


Vaccine that delivers an antigen (5T4) using a pox virus vector

Colorectal cancer

Company got approval for Phase II study in UK of 20 patients who are undergoing surgery for resectable liver metastases (1/16)

Wilex AG* (Germany)


Synthetic small-molecule inhibitor of serine proteases

Head and neck cancers

Company started a Phase Ib trial in Germany to assess safety, toler- ability and biological activity as a monotherapy (1/14)


GTC Biotherapeutics Inc. (GTCB)


Recombinant human antithrombin product produced in the milk of goats

Hereditary antithrombin deficiency

GTC submitted an approval application in Europe; the indication in HD patients is prophylaxis of deep-vein thrombosis and thromboembolism in clinical-risk situations (1/26)

Jerini AG* (Germany)

Icatibant (JE049)

Bradykinin-2 receptor antagonist

Hereditary angioedema

Company said angioedema symptoms resolved rapidly in all eight patients in the Phase II European trial (1/13)

United Therapeutics Corp.(UTHR)

Remodulin (FDA-approved)

Treprostinil sodium injection

Pulmonary arterial hypertension

French officials issued an action letter requesting additional information before product could be approved (1/6)


Labopharm Inc. (Canada; TSE:DDS)


Once-daily formulation of the analgesic tramadol


French authorities sent a letter asking for clarification on the approval request there (1/28)

NiCox SA (France; Nouveau Marche: NICOX)

NCX 4016

Nitric oxide-donating derivative of aspirin

Peripheral arterial obstructive disease

NiCox said Phase IIa trial in Italy reached its primary efficacy end- point of reversing endothelium dysfunction induced by physical exercise (1/8)

Pain Therapeutics Inc. (PTIE)


Capsule formulation of oxycodone, designed to be abuse-resistant


Company started a Phase I trial to assess safety and pharmacokinetics against placebo and active drug in healthy volunteers in the UK (1/15)


Amylin Pharmaceuticals Inc. (AMLN)


Pramlintide acetate; an analogue of human amylin


Swiss officials said they would not approve the product based on data received; Amylin withdrew its approval application (1/7)


Avant Immunotherapeutics Inc. (AVAN)


Single-dose oral vaccine


Avant released positive preliminary results from Phase II trial in 70 adults in Bangladesh; vaccine was well tolerated and more than 70% of adults had a favorable immune response (1/20)

Sinovac Biotech Inc.* (China; OTC BB:SNVBF)


Vaccine for severe acute respiratory syndrome


Company gained approval to initiate clinical trials in 30 subjects in China (1/20)

Stratus Research Labs Inc.*


Drug designed to target HIV-infected cells and put them in a nondividing state


Company said it was about to begin human trials in Latin Amer- ica (1/30)

VaxGen Inc. (VXGN)


Recombinantly produced anthrax vaccine


The FDA granted fast-track status to the product, for which VaxGen has government contracts to develop (1/21)


Aastrom Biosciences Inc. (ASTM)

Tissue Repair Cell

Stem and progenitor cells produced from samples of a patient's own bone marrow

Leg fractures

Company began trial in Germany in combination with a synthetic bone graft matrix in 10 patients with serious fractures (1/22)

Biolipox AB* (Sweden) and NiCox SA (France; Novuea Marche: NICOX)

NCX 1510

Agent delivered via nasal spray

Allergic rhinitis

Biolipox started a Phase IIa trial in 36 patients in Sweden to look at efficacy in an out-of-season allergen-provocation study (1/21)

Enhance Biotech Inc. (OTC BB:EBOI)

LI 301

Existing undisclosed drug

Premature ejaculation

Company said Phase IIa trial in Europe showed positive effect vs. placebo (1/27)

Genzyme Corp. (GENZ)

Fabrazyme (agalsidase beta)

Enzyme replacement therapy

Fabry's disease

Genzyme received approval to market the product in Japan as soon as officials there establish a price (1/29)

Proskelia SAS* (France)

PSK 3471

Selective estrogen receptor modulator


Company started a Phase IIa trial (1/28)**


* Privately held.

** Denotes the date item ran in BioWorld International.

Unless otherwise noted, the stock symbols listed for public companies are on the Nasdaq market.

AMEX = American Stock Exchange; ASX = Australian Stock Exchange; FSE = Frankfurt Stock Exchange; LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange.